PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its ...

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

PTC Therapeutics, Inc.’s PTCT share price has surged by 6.72%, which has investors questioning if this is right time to sell.

PTC today announced two new offerings from its cloud-native Onshape® computer-aided design (CAD) and product data management (PDM) platform: Onshape AI Advisor, an intelligent, generative AI-powered ...

In a report released today, Eric Joseph from J.P. Morgan maintained a Hold rating on Verve Therapeutics (VERV – Research Report), with a price ...

William Blair analyst Sami Corwin maintained a Hold rating on Applied Therapeutics (APLT – Research Report) today. The company’s shares closed ...

Learn more about whether Neurocrine Biosciences, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ ...